Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: SemiBull who wrote (1469)	4/16/2003 4:16:03 PM
From: software salesperson	Respond to of 3044

NEW YORK (Dow Jones)--Millennium Pharmaceuticals Inc. Chief Financial Officer Ken Bate said the company's first-quarter loss was deeper than Wall Street's estimates because analysts expected an earlier agreement to market one of its drugs. "Financial and operating results were in line with our estimates. Wall Street's expectations were different because of the timing of a Velcade partnership," said Bate, speaking shortly after the company's earnings release Tuesday. "We expected it in the second quarter, analysts expected it in the first quarter." what was this guy thinking, assuming that he was thinking at all? commenting on a missed # ? - - they want to encourage this nonsense each q ? blaming the analyst community ? - - when, in fact, there's no evidence for stating that they believed the deal would be in the 1 q misquoted ? set-up ? - - probably, just naive it doesn't look like we'll see many more interviews of this type for awhile lest we see a headline like: cfo slams street : street slams back sales